Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes
BOSTON, Oct. 30 /PRNewswire/ — Researchers from the University of Bari, Italy, concluded that treating patients after transplantation with antiviral therapy creates a sustained viral response (SVR) and protects them from liver-related deaths. The purpose of this study was to determine the long-term clinical outcomes of patients posttransplant who underwent antiviral therapy for recurrent hepatitis C virus (HCV) infection of the liver graft.
The use in clinical practice of antiviral therapy for HCV recurrence after liver transplantation is still controversial. Some favor antiviral therapy while data coming from meta-analysis of published studies do not recommend treatment in view of the frequent adverse effects and the lack of clinical benefit.
Maria Rendina, MD, on behalf of the AISF RECOLT-C Group, examined the records from 12 liver transplant centers in Italy over a 20-year period, and showed data on SVR and long-term clinical outcomes for a large posttransplantation patient population.
SVR was achieved in 35 percent of the 448 patients whose records were included in this study. Researchers noted that patients who achieved SVR received grafts from younger donors, received longer treatment duration and cumulative dose of interferon, and had a lower drop-out rate and lower incidence of diabetes; however there were no differences in immunosuppressive strategy for these patients.
Of the 134 patients who died since transplantation, 73 percent of those deaths were HCV related – and only one of those patients was able to achieve SVR. After univariate and multivariate analysis to correct for other variables, researchers demonstrated that patients with recurrent HCV who were unable to achieve SVR were at a high risk for liver-related deaths.
According to Dr. Rendina: “The results of the study are important as these data could have an impact on patient care: HCV viral eradication significantly protects patients from liver-related death and, therefore, must be strongly pursued. When asked about the future of research in this area, Dr. Rendina said, “Data from the AISF RECOLT-C Group provide a direction for further randomized clinical trials aimed at exploring various treatment options as well as the efficacy of new antivirals.”
SVR to antiviral therapy is highly protective against liver-related death in patients with HCV recurrence on the graft after liver transplantation (LT)
About the AASLD
AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD’s vision is to prevent and cure liver diseases. This year’s Liver MeetingÂ®, held in Boston, Massachusetts, October 29-November 2, will bring together more than 7,500 researchers from 55 countries.
A pressroom will be available from October 30 at the annual meeting. For copies of abstracts and press releases, or to arrange for pre-conference research interviews contact Gregory Bologna at 703-299-9766. To pre-register, call Ann Haran at 703-299-9766.
Press releases and all abstracts are available online at www.aasld.org.
Media Contact: Gregory Bologna 703-299-9766 email@example.com Press Room: October 30 - November 2, 2010 Hynes Convention Center, Room 208 Telephone: 617-954-3106 Researcher: Maria Rendina, MD University of Bari, Italy Email: firstname.lastname@example.org
This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.
SOURCE American Association for the Study of Liver Diseases (AASLD)